Skip to Content

Posts tagged with "Drug Industry History"

  • Academia (vs. Industry)

    How Much Basic Research?

    My long cri de couer last week continues to bring in a number of comments, which I appreciate. Matthew Holt of the Health Care Blog asks: How much money does the NIH spend on basic research and how much does the pharma business spend on it (and you can include development if you like)? I… Read More
  • Drug Industry History

    The State of the State of the Art

    This fall will mark my fifteenth year in the drug industry. Looking back at what things were like in late 1989, there’s one thing that I find striking above all the others: that very little has changed. Fifteen years is a pretty long time in the sciences. In a field like molecular biology it’s a… Read More
  • Drug Industry History

    Loose Lips

    A recent comment to the “Dumpster Diving for Data” post below mentioned a rumor that a supplier of oligonucleotides was comparing orders against GenBank sequences. For those outside the field, what all that means is that supposedly a company that makes custom small sequences of DNA was looking through a public DNA database, trying to… Read More
  • Drug Industry History

    Dumpster Diving for Data?

    A comment to the last post wondered if drug companies ever do active intelligence against each other (as opposed to the passive kinds I mentioned). Active means would be rooting through dumpsters and the like, and the answer is – almost invariably – no. That sort of thing is more trouble than it’s worth, because… Read More
  • Drug Assays

    What Ails Us

    Before getting started, I’d like to recommend the discussion going on in the Comments section of the “All the Myriad Ways” post below. If you find the topic of gene patents at all interesting, it’s worth keeping up with. Me, I’m just watching for now, feeling like Teresa Nielsen Hayden as the discussion takes off… Read More
  • Blog Housekeeping

    The Last Word on Taste

    No time for real blogging for today, but I couldn’t let this one go by: Reader Steve C. passes on what has to be one of the worst examples from the old days of tasting new compounds. Back in 1886, Victor Meyer was the first to achieve a reasonable synthesis of bis(2-chloroethyl)sulfide. So, as people… Read More
  • Drug Development

    The March of Folly Leader Board

    The first comment to the original March of Folly post below mirrors the e-mail I’ve received: the people’s choice for the technology most-likely-to-be-embarrassing is. . .(rustling of envelope): RNA interference. There’s a good case to be made for that, and it doesn’t contradict my oft-stated opinion that RNAi is going to be… Read More
  • Drug Industry History

    The March of Folly

    Thinking about molecular modeling, as I did in the last post, brings up another topic: when you go back to the late 1980s, in the real manic phase of the technological hype, what brings you up short is realizing that these folks were planning on doing all this with 1980s hardware. That puts things in… Read More
  • Drug Industry History

    Reality’s Revenge

    Molecular modeling is a technology with a past. Specifically, it’s a past of overoptimistic predictions (often made, to be fair, by people who didn’t understand what they were talking about.) Back in the late 1980s, when I started in the drug industry, modeling was going to take over the world and pretty darn soon, too. Read More
  • Cardiovascular Disease

    Ezetimibe, The Press, and More

    Credit where it’s due! Yesterday I mentioned the original chemist who started the ezetimibe story, but I should note that the drug itself was synthesized by another former colleague of mine, Stuart Rosenblum. He and a host of others developed a huge series of analogs, which built in more acitivity and greater in vivo stability. Read More